The CDC’s Advisory Committee on Immunization Practices renewed a recommendation for the use of the intranasal spray version of influenza vaccine (FluMist Quadrivalent, AstraZeneca) in the United States for the 2018-2019 season.
The vaccine was approved in 2003 and was part of the vaccination schedule for people 2 to 49 years of age until the 2016-2017 influenza season, when the ACPI withdrew its recommendation over concerns about the vaccine’s efficacy.
The new